Johnson & Johnson (JNJ) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Johnson & Johnson’s revenue went from $71.9B in fiscal 2016 to $94.2B in fiscal 2025, growth of about 3.0% a year.
Net income in fiscal 2025 was $26.8B, a net margin of 28.5%; the best year in this period was 2023 with $35.2B.
Over the twelve months to September 27, 2026, revenue was $99.3B and net income $16.1B.
Free cash flow was $19.7B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 13% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $99.3B | $94.2B | $88.8B | $85.2B | $80.0B | $78.7B | $82.6B | $82.1B | $81.6B | $76.5B | $71.9B |
| Gross profit | $67.1B | $63.9B | $61.4B | $58.6B | $55.4B | $55.3B | $54.2B | $54.5B | $54.5B | $51.0B | $50.1B |
| Operating income | $18.7B | $33.6B | $17.4B | $15.8B | $19.6B | $19.4B | $16.7B | $17.6B | $19.0B | $18.6B | $20.5B |
| Net income | $16.1B | $26.8B | $14.1B | $35.2B | $17.9B | $20.9B | $14.7B | $15.1B | $15.3B | $1.3B | $16.5B |
| EPS (diluted) | $6.59 | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 |
| R&D | $16.1B | $109M | $1.8B | $483M | $0 | $0 | $12.2B | $11.4B | $10.8B | $10.6B | $9.1B |
| Revenue growth | — | +6.0% | +4.3% | +6.5% | +1.6% | −4.7% | +0.6% | +0.6% | +6.7% | +6.3% | +2.6% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $26.2B | $24.5B | $24.3B | $22.8B | $21.2B | $23.4B | $23.5B | $23.4B | $22.2B | $21.1B | $18.8B |
| Capital spending | -$5.6B | -$4.8B | -$4.4B | -$4.5B | -$4.0B | -$3.7B | -$3.3B | -$3.5B | -$3.7B | -$3.3B | -$3.2B |
| Free cash flow | $20.6B | $19.7B | $19.8B | $18.2B | $17.2B | $19.8B | $20.2B | $19.9B | $18.5B | $17.8B | $15.5B |
| Dividends paid | $12.7B | $12.4B | $11.8B | $11.8B | $11.7B | $11.0B | $10.5B | $9.9B | $9.5B | $8.9B | $8.6B |
| Buybacks | $7.9B | $6.0B | $2.4B | $5.1B | $6.0B | $3.5B | $3.2B | $6.7B | $5.9B | $6.4B | $9.0B |
| Stock-based pay | $1.4B | $1.4B | $1.2B | $1.2B | $1.1B | $1.1B | $1.0B | $977M | $978M | $962M | $878M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $20.1B | $24.5B | $22.9B | $22.3B | $31.6B | $25.2B | $19.3B | $19.7B | $18.3B | $41.9B |
| Debt | — | $42.8B | $33.6B | $28.4B | $29.7B | $33.1B | $35.5B | $28.7B | $30.3B | $32.2B | $24.1B |
| Equity | — | $81.5B | $71.5B | $68.8B | $76.8B | $74.0B | $63.3B | $59.5B | $59.8B | $60.2B | $70.4B |
| Total assets | — | $199.2B | $180.1B | $167.6B | $187.4B | $182.0B | $174.9B | $157.7B | $153.0B | $157.3B | $141.2B |
| Shares (diluted) | 2.45B | 2.43B | 2.43B | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B | 2.73B | 2.75B | 2.79B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 67.6% | 67.9% | 69.1% | 68.8% | 69.2% | 70.3% | 65.6% | 66.4% | 66.8% | 66.7% | 69.7% |
| Operating margin | 18.8% | 35.6% | 19.6% | 18.6% | 24.6% | 24.6% | 20.2% | 21.5% | 23.3% | 24.3% | 28.6% |
| Net margin | 16.2% | 28.5% | 15.8% | 41.3% | 22.4% | 26.5% | 17.8% | 18.4% | 18.8% | 1.7% | 23.0% |
| FCF margin | 20.7% | 20.9% | 22.3% | 21.4% | 21.5% | 25.1% | 24.4% | 24.3% | 22.7% | 23.2% | 21.6% |
| ROIC | — | 22.2% | 14.0% | 14.4% | 15.6% | 16.8% | 15.1% | 17.5% | 17.9% | 15.9% | 18.1% |
| ROE | — | 32.9% | 19.7% | 51.1% | 23.4% | 28.2% | 23.2% | 25.4% | 25.6% | 2.2% | 23.5% |
Frequently asked questions
What is Johnson & Johnson’s annual revenue?
$94.2B in fiscal 2025 and $99.3B over the twelve months to September 27, 2026.
How much profit does Johnson & Johnson make?
Net income was $26.8B in fiscal 2025 (net margin 28.5%).
Is Johnson & Johnson’s revenue growing?
Yes: revenue rose 6.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.